UBS analyst Kevin Caliendo lowered the firm’s price target on Humana to $530 from $585 and keeps a Buy rating on the shares following the company’s 2023 EPS and open enrollment update. The firm believes Humana will return to more normalized earnings growth in 2025, but UBS does not expect an outsized bounceback, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on HUM:
- Humana Forecasts Medicare Advantage Membership Growth
- 3 Best Stocks to Buy Now, 1/19/2024, According to Top Analysts
- Humana Stock (NYSE:HUM) Under $400 Looks Like a Great Deal
- Humana’s (NYSE:HUM) Bleak Q4 Forecast Sends Ripples Across the Industry
- Humana says emerging utilization trends are ‘impacting the industry broadly’